Health
U.S. to End Vaccine Funds for Poor Countries
The Trump administration intends to terminate the United States’ financial support for Gavi, the organization that has helped purchase critical vaccines for children in developing countries, saving millions of lives over the past quarter century, and to significantly scale back support for efforts to combat malaria, one of the biggest killers globally.
The administration has decided to continue some key grants for medications to treat H.I.V. and tuberculosis, and food aid to countries facing civil wars and natural disasters.
Those decisions are included in a 281-page spreadsheet that the United States Agency for International Development sent to Congress Monday night, listing the foreign aid projects it plans to continue and to terminate. The New York Times obtained a copy of the spreadsheet and other documents describing the plans.
The documents provide a sweeping overview of the extraordinary scale of the administration’s retreat from a half-century-long effort to present the United States to the developing world as a compassionate ally and to lead the fight against infectious diseases that kill millions of people annually.
The cover letter details the skeletal remains of U.S.A.I.D. after the cuts, with most of its funding eliminated, and only 869 of more than 6,000 employees still on active duty.
In all, the administration has decided to continue 898 U.S.A.I.D. awards and to end 5,341, the letter says. It says the remaining programs are worth up to $78 billion. But only $8.3 billion of that is unobligated funds — money still available to disburse. Because that amount covers awards that run several years into the future, the figure suggests a massive reduction in the $40 billion that U.S.A.I.D. used to spend annually.
A spokesperson for the State Department, which now runs what is left of U.S.A.I.D., confirmed the terminations on the list were accurate and said that “each award terminated was reviewed individually for alignment with agency and administration priorities, and terminations were executed where Secretary Rubio determined the award was inconsistent with the national interest or agency policy priorities.”
The memo to Congress presents the plan for foreign assistance as a unilateral decision. However because spending on individual health programs such as H.I.V. or vaccination is congressionally allocated, it is not clear that the administration has legal power to end those programs. This issue is currently being litigated in multiple court challenges.
Among the programs terminated is funding for the United Nations Food and Agriculture Organization, which conducts surveillance for diseases that can be transmitted from animals to humans, including bird flu, in 49 countries. Some major programs to track and fight malaria, one of the world’s top killers of children, have also been ended.
Dr. Austin Demby, the health minister of Sierra Leone, which relies on Gavi’s support to help purchase vaccines, said he was “shocked and perturbed” by the decision to terminate U.S. funding and warned that the ramifications would be felt worldwide.
“This is not just a bureaucratic decision, there are children’s lives at stake, global health security will be at stake,” he said. “Supporting Gavi in Sierra Leone is not just a Sierra Leone issue, it’s something the region, the world, benefits from.”
In addition to trying to reach all children with routine immunizations, Sierra Leone is currently battling an mpox outbreak, for which Gavi has provided both vaccines and critical support to deliver them, he said.
“We hope the U.S. government will continue to be the global leader it always been — putting money in Gavi is not an expenditure, it’s an investment,” Dr. Demby said
Gavi is estimated to have saved the lives of 19 million children since it was set up 25 years ago. The United States contributes 13 percent of its budget.
The terminated grant to Gavi was worth $2.6 billion through 2030. Gavi was counting on a pledge made last year by President Joseph R. Biden Jr. for its next funding cycle.
New vaccines with the promise to save millions of lives in low-income countries, such as one to protect children from severe malaria and another to protect teenage girls against the virus that causes cervical cancer, have recently become available, and Gavi was expanding the portfolio of support it could give those countries.
The loss of U.S. funds will set back the organization’s ability to continue to provide its basic range of services — such as immunization for measles and polio — to a growing population of children in the poorest countries, let alone expand to include new vaccines.
By Gavi’s own estimate, the loss of U.S. support may mean 75 million children do not receive routine vaccinations in the next five years, with more than 1.2 million children dying as a result.
The U.S. has been among the top donors to the organization since its creation, and became the largest during the Covid-19 pandemic. While European countries have historically provided significant funding, many are now reducing foreign aid spending as they grapple with the change in U.S. policy on Ukraine and the U.S. demand that they increase their defense spending. Japan, another major Gavi donor, is struggling with a depreciating currency.
Dr. Sania Nishtar, Gavi’s chief executive, said that she hoped the Trump administration would reconsider the decision to end its support. Gavi’s work keeps people everywhere, including Americans, safe, she said. In addition to protecting individual children, vaccination reduces the possibility of large outbreaks. The organization maintains global stockpiles for vaccines against diseases such as Ebola and cholera, deploying them in rapid response efforts for epidemics.
Gavi’s structure requires countries to pay part of the cost of vaccines, with their share growing as income levels rise; middle-income countries are weaned from support.
Although the administration has repeatedly said publicly that its foreign assistance review process has been concluded, the information in the documents suggests that there is still some fluidity in which programs will survive. Staff members of one major malaria program that was terminated weeks ago, and which appears on the list of canceled projects sent to Congress, for example, were informed on Monday that it is being restored.
Nevertheless, cuts to malaria response are deep. While awards that fund the bulk purchase of bednets and malaria treatments have been preserved, many of the programs to deliver these and other malaria control efforts in individual countries such as Cameroon and Tanzania — among the most affected in the world — have been terminated. Some organizations with awards that have not been officially canceled have received no funds for more than two months, and have folded. Without them, there is no one to take treatments from ports to local clinics, or deliver them to children.
The memo says that 869 U.S.A.I.D. personnel were working as of last Friday, while 3,848 were on administrative leave and 1,602 are in the process of being laid off. Of 300 probationary employees who were initially fired, 270 have returned to work following a court order prohibiting their dismissal.
Health
Will Her Daughter Be Safe at Pali High as It Rebuilds From LA Wildfires?
One morning just before Christmas, Michelle stood in a Thrifty-Wash, watching her seven loads of laundry tumble and spin. The machine at the Airbnb had broken and flooded the place. It had been a blessing, in a way — Michelle needed this time alone to think.
The night before, Los Angeles Unified School District officials had hosted a Zoom webinar for parents, in which they had promised to present all the evidence that campus was safe. Michelle had gone in with high hopes, maybe even optimism. Afterward, she called it “the Zoom from hell.”
The officials had opened the meeting by announcing that Pali High’s students would go back to campus at the end of January. Michelle had peered at the screen, squinting to make sense of their color-coded maps, charts and checklists as district officials and their third-party contractors used wonky terms to describe what sounded to Michelle like rudimentary decontamination methods: “visual inspections,” “glove tests,” “subjective evaluations for smoke odor” and the copious use of wet wipes.
The “Environmental Concerns” WhatsApp group began pinging with live commentary. “It’s like they’re all hanging out with my insurance company,” one mother typed. “Transparency my a$$,” wrote another.
During the question-and-answer portion, parents flooded the submission box: Why weren’t the porous ceiling tiles removed? (“We did our best to remove any surface contaminants that we could see visually,” one contractor replied.) Did they realize that lithium had been detected in smoke-damaged homes near the school? (“Lithium, we determined, was not going to be a high-priority metal for us,” another contractor explained.) And why hadn’t they tested for benzene, carbon tetrachloride or perchloroethylene — some of which had been found in other Palisades buildings after the fires?
Michelle had a hunch she knew the answer, but she assumed no official would ever admit it. Then the project manager for one of the contractors came on the screen.
“There are hundreds — literally — of different compounds that could be produced during a fire,” he said, “and there are analytical methods that can be very, very precise in sampling for those.” But the problem, he said, was that it “lacks specificity in what we can actually deal with … ”
Michelle had shaken her head in disbelief. The project manager interrupted himself. “That was the wrong way to put that,” he muttered.
This morning, Michelle had waked to some parents on the “Environmental Concerns” chat talking about putting their kids in virtual learning. Others were hoping to transfer. Michelle was fantasizing about protesting the return to campus, even dreaming up the picket signs: “Lead should only be in pencils,” or maybe, “Test on the school, not on the kids.”
Health
Experimental obesity drug outperforms traditional weight-loss treatments in early research
NEWYou can now listen to Fox News articles!
A new weight-loss drug variation is showing promise in early trials.
Research from the Institute for Diabetes and Obesity at Helmholtz Munich in Germany, published in the journal Nature, tested an experimental obesity and diabetes drug called GLP-1-GIP-Lani.
The drug combines GLP-1 and GIP — two natural hormones that help regulate appetite and blood sugar, similar to popular weight-loss drugs like Ozempic — with PPAR activity, which may improve insulin sensitivity, inflammation, fat metabolism and liver health.
‘NEXT OZEMPIC’ AIMS TO DELIVER 30% WEIGHT LOSS WITH FEWER SIDE EFFECTS
The team of researchers, led by Professor Timo D. Muller at Helmoltz Munich, called the drug a quintuple agonist, as it targets five receptor systems.
In a press release, Muller described the drug as a “Trojan horse”: the incretin component — hormones that help regulate blood sugar and appetite — allows it to enter target cells, and once inside, the PPAR “cargo” activates to help the body better use insulin, process fat and reduce inflammation.
The researchers hope the “Trojan horse” effect will allow for lower dosing and fewer side effects. (iStock)
This allows for the dosage of the drug to be lower, which could reduce side effects.
“A major advantage is the amount,” Muller said. “Because the second component is not administered separately and systemically, but ‘travels along’ with the incretin part, it can be used at a dose that is orders of magnitude lower.”
NEW WEIGHT-LOSS SHOT SHOWS MAJOR FAT REDUCTION, BUT EXPERTS URGE CAUTION
The study tested the drug combination in mouse models, including mice with diabetes-induced obesity, insulin resistance and genetic obesity.
In these mice, the compound was found to lower body weight, food intake, fat mass, blood sugar and insulin-related problems more than GLP-1 and GIP alone. It also outperformed semaglutide.
CLICK HERE FOR MORE HEALTH STORIES
The researchers reported that typical gastrointestinal side effects were similar to those seen with existing therapies.
“We see a principle with strong effects in the animal model — now the task is to optimize the approach for humans and move it toward the clinic,” Muller said in the release.
The preclinical study was conducted in mouse models and cannot yet be applied to humans. (iStock)
Dr. Peter Balazs, MD, a hormone and weight-loss specialist practicing in New York and New Jersey, said the drug is designed to target obesity and insulin resistance “at multiple key sites simultaneously, including the brain, pancreas and metabolic tissues.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“This is a novel mechanism because it’s not just relying on a higher dose of an existing drug,” he told Fox News Digital in an interview.
“Current GLP-1 medications are highly effective appetite suppressants, while this quintuple agonist seems to function both as an ‘appetite brake’ and a metabolic engine,” he added.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
While traditional GLP-1s primarily reduce appetite, slow gastric emptying and increase insulin secretion, this quintuple agonist “appears to do all of the above” while also “directly improving insulin sensitivity in the liver and muscle, reducing inflammation in adipose tissue and remodeling lipid metabolism,” the expert confirmed.
While traditional GLP-1s primarily reduce appetite, slow gastric emptying and increase insulin secretion, this quintuple agonist “appears to do all of the above,” an expert said. (iStock)
“The result may be greater weight loss through a combination of caloric restriction, enhanced fat oxidation and potentially increased central energy expenditure,” Balazs said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Although the drug provides a “promising direction for the future,” Balazs noted that the study was conducted only on mouse models and there is no human safety or efficacy data, which means the drug cannot yet be recommended for clinical use.
“Additionally, it was conducted over a relatively short period of time, so we cannot draw conclusions about long-term effects,” he added.
Health
With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win
Over lunch at his golf club in Jupiter, Fla., on the first Saturday of May, President Trump got an earful from a group of tobacco executives and lobbyists unhappy with the way the Food and Drug Administration was regulating their industry.
Eventually Mr. Trump had heard enough. He interrupted the conversation to call Dr. Marty Makary, the F.D.A. commissioner.
No answer.
Furious, the president then dialed Dr. Makary’s boss, Health Secretary Robert F. Kennedy Jr., and another top health official, Dr. Mehmet Oz, the head of the Centers for Medicare and Medicaid Services. He complained to them about the F.D.A.’s regulation of e-cigarettes, according to three people briefed on the meeting who were not authorized to discuss it.
The message was received. Less than one week later, the executives got what they wanted.
On Friday, the F.D.A. issued new guidance that could pave the way for major tobacco companies to begin selling flavored vapes and to snare a chunk of the $6 billion e-cigarette market away from illegal Chinese competitors. The new policy bypassed the F.D.A.’s regular rule-making process.
In the intervening week, Dr. Makary continued to argue against approving flavored vapes as support from Mr. Kennedy and others collapsed around him. Health and Human Services Department staff began to draft the new plan, according to two people familiar with the events.
On Tuesday, Dr. Makary resigned, telling associates he could not in good conscience remain the head of an agency that backed such a policy.
Though there is no definitive evidence linking the new guidance to donations or lobbying, the episode represented a clear pivot in the federal government’s longtime approach to the tobacco industry.
Since the 1990s, when states extracted vast payments and other concessions from the major cigarette companies in a nationwide legal settlement, Big Tobacco has been in retreat. Cigarette sales have plummeted, and regulations have mounted as consumers and administrations from both parties embraced public health consensus about the dangers of smoking and nicotine addiction.
Mr. Trump’s first administration initially continued the trend, proposing further restrictions on cigarettes and moving to outlaw flavored vapes over concerns that their rising popularity threatened the health of a generation of adolescents.
But since then, Mr. Trump has enthusiastically welcomed the financial support of the tobacco industry and has courted e-cigarette users as a political constituency.
The new vaping guidance highlights Mr. Trump’s willingness to use his executive authority to prioritize the causes of major corporate donors over public health concerns, taxpayer interests and the judgment of experts, sometimes including those in his own administration.
The president has developed a close relationship with tobacco companies including Altria and Reynolds American, which have donated millions of dollars to his political groups and projects, including his proposed White House ballroom. Their executives attended the lunch at the president’s golf club.
The Department of Health and Human Services, which oversees the F.D.A., referred requests for comment to the White House.
Kush Desai, a White House spokesman, said in a statement that Mr. Trump has pushed to expand access to vapes to help Americans trying to quit smoking.
“The only guiding factor behind the Trump administration’s health policymaking is gold standard science,” Mr. Desai said.
Reynolds American and Altria did not respond to questions about their lobbying or the conversation at the lunch.
It was attended by Jeff Raborn, a top executive at Reynolds, and Phil Park and Todd Walker of Altria, according to the people familiar with the meeting. Also attending were Brian Ballard and Rich Haselwood, lobbyists for the firm Ballard Partners, which represents Reynolds and helped marshal a sophisticated and expensive influence campaign that culminated in the new vaping guidance. Mr. Ballard is a top fund-raiser for Mr. Trump. Mr. Haselwood had been an in-house lobbyist at Reynolds before joining Ballard Partners this year.
A spokesman for Ballard Partners declined to comment.
While public health experts consider e-cigarettes a less harmful alternative to tobacco-burning cigarettes, the new guidance circumvents a scientific review process the F.D.A. had previously defended up to the Supreme Court. The disregarded procedures were meant to ensure approval of only those products shown in studies to help cigarette smokers transition to vapes without attracting a new generation of nicotine users.
The guidance also could allow higher nicotine levels in nicotine pouches. It includes a pledge to prioritize efforts to stop the import of illegal foreign vapes, an idea that has bipartisan support in Congress.
Taken together, the policy changes could help companies like Altria and Reynolds gain market share considered central to the survival of the industry.
The market for vapes and nicotine pouches, like Zyn, is about 30 million people in the United States, on par with the number of cigarette smokers. While the nicotine pouch market is rapidly growing, cigarettes still account for about $50.8 billion, or nearly 70 percent of the annual tobacco sales in the United States, according to a Goldman Sachs research report. Vape sales have lagged amid competition from illicit products.
In recent years, the F.D.A. has moved glacially to approve e-cigarettes, authorizing only those in tobacco or menthol flavors, including some sold by Reynolds and Altria. Unapproved Chinese vapes have poured into the United States, feeding a thriving illicit market with flavors like peach slush and watermelon ice. Last year, industry executives have said, illicit fruit-flavored vapes made up 60 percent of the e-cigarette market.
When Mr. Trump mounted his bid to return to the White House, some in the tobacco industry went all in, hoping he would loosen regulations on vapes and abandon plans by the Biden administration to ban menthol cigarettes and crack down on other cigarette sales.
Mr. Trump in some ways makes for an unlikely savior for the tobacco industry. He has never smoked, but he pledged during his 2024 campaign to “save vaping again.”
Through a subsidiary, Reynolds, which is the biggest seller of menthol cigarettes, donated $10 million to a super PAC backing Mr. Trump’s campaign, according to campaign finance filings. There is no public record of the subsidiary donating to groups supporting Mr. Biden or the campaign of former Vice President Kamala Harris.
Mr. Ballard, whose firm has been paid more than $4.4 million by Reynolds since the beginning of 2017, arranged for Mr. Trump to have dinner during the campaign with Reynolds executives in New York, according to a person familiar with the interactions. The executives urged Mr. Trump to oppose the menthol cigarette ban and expressed concern about Chinese vapes.
Reynolds executives including Mr. Raborn and Mr. Haselwood were such a presence around the campaign that Mr. Trump took to calling them “my tobacco guys,” according to the person familiar with the interactions and a book coauthored by a New York Times reporter and published last year.
When Mr. Trump won, the rest of the industry jockeyed to show support.
Altria donated $1 million to his inaugural committee; the Vapor Technology Association donated $1.25 million; and a subsidiary of Philip Morris donated $500,000.
On Mr. Trump’s second full day in office, his administration withdrew the proposed ban on menthol cigarettes, an initiative the Biden administration had already mostly abandoned. Mr. Trump’s team also set aside a Biden-era proposal to sharply restrict nicotine in cigarettes, an effort meant to speed the transition away from a product known to be deadly.
In applauding the withdrawal of the menthol ban, Billy Gifford, the chief executive of Altria, told investors on an April 2025 earnings call that “we’re hopeful that that activity and momentum continues.”
The courtship intensified.
Reynolds pitched in another $3 million to a different Trump-backed super PAC, while Altria and Juul each donated $1 million.
And Reynolds and Altria each donated to the effort to raise private funds to build a new White House ballroom. Mr. Raborn of Reynolds and Mr. Walker of Altria were invited to a dinner at the White House in October for donors who gave $2.5 million or more, as was Mr. Ballard.
Tadeu Marroco, the chief executive of British American Tobacco, which owns Reynolds American, predicted to investors earlier this year that the Trump administration would clamp down on illegal vapes, saying “it’s very encouraging, the signs that the new administration is giving to address that.”
The companies’ lobbying strategy also has reached into the states, where they are pushing for so-called “registry laws” — of which there are now more than a dozen including in Florida, Virginia and Pennsylvania. Many of those laws restrict e-cigarette sales to only vapes on a list from the F.D.A.
The guidance released last week said it would create such a list.
Sheryl Gay Stolberg contributed reporting.
-
Pennsylvania4 minutes agoMan arrested for allegedly posting hit list, threatening more than a dozen Pennsylvania lawmakers
-
Rhode Island10 minutes ago
Star-studded cast of ‘My Boyfriend is a Demon,’ filming in RI, released
-
South-Carolina16 minutes agoReady, Set, Vote! Your Guide to the (Evolving) South Carolina Ballot – FITSNews
-
South Dakota22 minutes agoHomeschool SD Conference kicks off with free concert Friday at The Monument
-
Tennessee28 minutes agoTennessee bishops push for halt of execution
-
Texas34 minutes ago‘We have great support’: Coach Bucky speaks at Dallas A&M Club event
-
Utah40 minutes agoUtah Royals FC Returns Home to Host Racing Louisville FC Chasing Eight Match Unbeaten Streak | Utah Royals
-
Vermont46 minutes agoSt. Joseph’s Orphanage exhibit opens at Vermont Police Academy